AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 832836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-reduced formula
Number of subjects: 40
Study 832836 — intervention group
Group type: COMPARATOR
Intervention: Comparative formula
Number of subjects: 40
Study 31092112 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ intervention (n = 37)
Number of subjects: 71
Study 31092112 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 34)
Number of subjects: 71
Study 31055211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-Flow (low-viscosity bulk-fill resin composite) applied with ∼3.5 mm-thick first increment and two final increments of Opallis (∼1.5 mm-thick)
Number of subjects: 40
Study 31055211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-Regular (bulk-fill resin composite of regular viscosity) applied using a single increment of 5 mm-thick
Number of subjects: 40
Study 31055211 — intervention group
Group type: COMPARATOR
Intervention: Positive control (conventional resin composite Opallis) applied using increments of up to 2.0 mm-thick
Number of subjects: 40
Study 31055211 — intervention group
Group type: COMPARATOR
Intervention: Negative control (without restoration)
Number of subjects: 40
Study 28133708 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg on-demand tadalafil (OD-TAD)
Number of subjects: 43
Study 28133708 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg daily tadalafil (OAD-TAD)
Number of subjects: 43
Study 28133708 — intervention group
Group type: COMPARATOR
Intervention: C2C12 cells exposed to increasing tadalafil concentrations (10-7 to 10-6 M)
Number of subjects: 43
Study 25449847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (sweet, no energy)
Number of subjects: 30
Study 25449847 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin (non-sweet, energy)
Number of subjects: 30
Study 25449847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose + Maltodextrin (sweet, energy)
Number of subjects: 30
Study 25449847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger state
Number of subjects: 30
Study 25449847 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy tasting during satiety
Number of subjects: 30
Study 23583245 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (DES)
Number of subjects: 236
Study 23583245 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 236
Study 23583245 — intervention group
Group type: COMPARATOR
Intervention: Provisional bare-metal stent (BMS)
Number of subjects: 236
Study 23583245 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (DES) in single-arm study
Number of subjects: 236
Study 23583245 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (DES) in RCT
Number of subjects: 236
Study 21816087 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-based strategy (RDTs)
Number of subjects: 2169
Study 21816087 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumptive treatment for all
Number of subjects: 2169
Study 19622756 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 0
Study 17317827 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva samples from patients with HNSCC
Number of subjects: 120
Study 17317827 — intervention group
Group type: COMPARATOR
Intervention: Control saliva samples from patients with nonmalignant head and neck pathology
Number of subjects: 120
Study 15075995 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection prevalence
Number of subjects: 353
Study 15075995 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a risk factor for H. pylori infection
Number of subjects: 353
Study 15075995 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of persons per room as a risk factor for H. pylori infection
Number of subjects: 353
Study 12610183 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (C; 75 mg/m(2) orally days 1 to 14), epirubicin (E; 60 mg/m(2) IV days 1, 8), and fluorouracil (F; 500 mg/m(2) IV days 1, 8) - CEF arm
Number of subjects: 448
Study 12610183 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (E; 120 mg/m(2) IV day 1), Cyclophosphamide (C; 830 mg/m(2) IV day 1), and filgrastim (5 micro g/kg/d subcutaneously days 2 to 13) - EC arm
Number of subjects: 448
Study 9921379 — intervention group
Group type: EXPERIMENTAL
Intervention: Various motor vehicle injury prevention strategies; specific strategies not detailed
Number of subjects: 1100
Study 9921379 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; few randomized controlled trials found
Number of subjects: 1100
Study 7598918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg
Number of subjects: 34
Study 2397624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dead Sea bath salts
Number of subjects: 30
Study 2397624 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 30
Study 274270 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 41
Study 274270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptic
Number of subjects: 41
Study 274270 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Cap
Number of subjects: 41
Study 274270 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoxydent
Number of subjects: 41
Study 274270 — intervention group
Group type: COMPARATOR
Intervention: Amalgam and Adaptic
Number of subjects: 41
Study 31204284 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=160)
Number of subjects: 314
Study 31204284 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=154)
Number of subjects: 314
Study 31204284 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between groups
Number of subjects: 314
Study 28732521 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroclavicular approach
Number of subjects: 98
Study 28732521 — intervention group
Group type: COMPARATOR
Intervention: Infraclavicular approach
Number of subjects: 98
Study 25951605 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor-made notched music (TMNM)
Number of subjects: 18
Study 25951605 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased spectral energy contrasts in tailor-made notched music (ISEC-TMNM)
Number of subjects: 18
Study 25951605 — intervention group
Group type: COMPARATOR
Intervention: Classical TMNM
Number of subjects: 18
Study 23998433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol (1 g) plus intravenous ketorolac (30 mg i.v. once daily)
Number of subjects: 120
Study 23998433 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac (30 mg i.v. once daily) alone
Number of subjects: 120
Study 21558299 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT measured at 1 min after heparin injection
Number of subjects: 50
Study 21558299 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT measured at 2 min after heparin injection
Number of subjects: 50
Study 21558299 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT measured at 3 min after heparin injection
Number of subjects: 50
Study 21558299 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT measured at 4 min after heparin injection
Number of subjects: 50
Study 21558299 — intervention group
Group type: COMPARATOR
Intervention: ACT measured at 5 min after heparin injection
Number of subjects: 50
Study 19746676 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg drospirenone plus 20 microg ethinylestradiol (24/4 regimen)
Number of subjects: 538
Study 19746676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 17488807 — intervention group
Group type: EXPERIMENTAL
Intervention: ExHypo (12 weeks of supervised aerobic exercise combined with a hypocaloric diet, approximately 500 kcal reduction, n = 11)
Number of subjects: 21
Study 17488807 — intervention group
Group type: EXPERIMENTAL
Intervention: ExEu (12 weeks of supervised aerobic exercise combined with a eucaloric diet, n = 10)
Number of subjects: 21
Study 15453553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pharyngoplasty
Number of subjects: 27
Study 15453553 — intervention group
Group type: COMPARATOR
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 27
Study 11435053 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide
Number of subjects: 62
Study 11435053 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm inhaled nitric oxide
Number of subjects: 62
Study 11435053 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ppm inhaled nitric oxide
Number of subjects: 62
Study 11435053 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ppm inhaled nitric oxide
Number of subjects: 62
Study 11435053 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (control group)
Number of subjects: 62
Study 9512323 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 microgram rectally
Number of subjects: 491
Study 9512323 — intervention group
Group type: COMPARATOR
Intervention: Syntometrine 1 ampoule intramuscularly
Number of subjects: 491
Study 8037411 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 50
Study 8037411 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 50
Study 8037411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac and Aspirin
Number of subjects: 50
Study 31958336 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased combined levels of serum uric acid (SUA) and alanine aminotransferase (ALT)
Number of subjects: 3998
Study 31958336 — intervention group
Group type: COMPARATOR
Intervention: Increased levels of serum uric acid (SUA) alone
Number of subjects: 3998
Study 31958336 — intervention group
Group type: COMPARATOR
Intervention: Increased levels of alanine aminotransferase (ALT) alone
Number of subjects: 3998
Study 30477915 — intervention group
Group type: EXPERIMENTAL
Intervention: AUGMENT (autologous mitochondrial transfer)
Number of subjects: 59
Study 30477915 — intervention group
Group type: COMPARATOR
Intervention: Control (intracytoplasmic sperm injection)
Number of subjects: 59
Study 30477915 — intervention group
Group type: EXPERIMENTAL
Intervention: AUGMENT
Number of subjects: 59
Study 30477915 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 28178058 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 2013
Study 28178058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study 26214550 — intervention group
Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 45
Study 26214550 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves (outer pair removed after intubation)
Number of subjects: 45
Study 26214550 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves with sheathing
Number of subjects: 45
Study 23393007 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 51
Study 23393007 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 51
Study 23393007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (real and sham acupuncture)
Number of subjects: 51
Study 21698991 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (Vitremer) as occlusal sealant
Number of subjects: 268
Study 21698991 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (Duraphat) application
Number of subjects: 268
Study 21698991 — intervention group
Group type: COMPARATOR
Intervention: Oral health education (OHE) every 3 months
Number of subjects: 268
Study 19330582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pennebaker writing intervention
Number of subjects: 28
Study 19330582 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 28
Study 16788338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 96
Study 16788338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 15299054 — intervention group
Group type: EXPERIMENTAL
Intervention: RBI without AC
Number of subjects: 20
Study 15299054 — intervention group
Group type: EXPERIMENTAL
Intervention: dSPECT
Number of subjects: 20
Study 15299054 — intervention group
Group type: EXPERIMENTAL
Intervention: RBI with AC
Number of subjects: 20
Study 15299054 — intervention group
Group type: COMPARATOR
Intervention: FBP
Number of subjects: 20
Study 10946429 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions against infectious diseases in cluster-randomized trials
Number of subjects: 0
Study 10946429 — intervention group
Group type: COMPARATOR
Intervention: Cluster-randomized trials (CRTs)
Number of subjects: 0
Study 9049584 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole 400 mg
Number of subjects: 9
Study 9049584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole 400 mg
Number of subjects: 9
Study 9049584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral and intravenous)
Number of subjects: 9
Study 8349330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish or fish oil supplements (6 or 12 fish-oil capsules daily, fish meals providing 1.3 g of eicosapentaenoic acid, or a combination of fish oil and fish)
Number of subjects: 120
Study 8349330 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 120
Study 2939691 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine (100 mg b.i.d.)
Number of subjects: 75
Study 2939691 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (75 mg b.i.d.)
Number of subjects: 75
Study 30554581 — intervention group
Group type: EXPERIMENTAL
Intervention: si-SOX9
Number of subjects: 0
Study 30554581 — intervention group
Group type: EXPERIMENTAL
Intervention: As2O3
Number of subjects: 0
Study 30554581 — intervention group
Group type: EXPERIMENTAL
Intervention: si-SOX9 combined with As2O3
Number of subjects: 0
Study 30554581 — intervention group
Group type: COMPARATOR
Intervention: blank group
Number of subjects: 0
Study 27356143 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin (1 U/cm2 wound area), applied twice daily for 7 days.
Number of subjects: 50
Study 27356143 — intervention group
Group type: COMPARATOR
Intervention: Normal saline dressing (control group), applied twice daily for 7 days.
Number of subjects: 50
Study 24655465 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led Body Project groups (Study 1)
Number of subjects: 615
Study 24655465 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led Body Project groups (Study 2)
Number of subjects: 615
Study 24655465 — intervention group
Group type: COMPARATOR
Intervention: Educational control group (Study 1)
Number of subjects: 615
Study 24655465 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (Study 2)
Number of subjects: 615
Study 22583520 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based training plus supervision
Number of subjects: 168
Study 22583520 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based training
Number of subjects: 168
Study 22583520 — intervention group
Group type: COMPARATOR
Intervention: training‐as‐usual (control)
Number of subjects: 168
Study 20433665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural intervention (CI) delivered by Spanish-speaking nurses at 9 clinic visits
Number of subjects: 86
Study 20433665 — intervention group
Group type: COMPARATOR
Intervention: Historical sample (control group) of 131 clients' records from the previous year
Number of subjects: 86
Study 19076574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve block of the auricular branch of the Vagus (Nerve of Arnold) with 0.2 ml of 0.25% bupivacaine
Number of subjects: 200
Study 19076574 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fentanyl 2 mcg.kg(‐1)
Number of subjects: 200
Study 16115360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (providing 2.7 g/d EPA and DHA) plus antioxidants (vitamins A, C and E, and Se)
Number of subjects: 61
Study 16115360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11990448 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods to modulate the host response in periodontal therapy
Number of subjects: 0
Study 10084566 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term fasting (2.5-day)
Number of subjects: 8
Study 7486080 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine hydrochloride (1 mM) added to St. Thomas' Hospital cardioplegic solution II (Plegisol)
Number of subjects: 56
Study 7486080 — intervention group
Group type: COMPARATOR
Intervention: Saline added to St. Thomas' Hospital cardioplegic solution II (Plegisol)
Number of subjects: 56
Study 2119786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-aural group
Number of subjects: 0
Study 2119786 — intervention group
Group type: EXPERIMENTAL
Intervention: English sign language group
Number of subjects: 0
Study 2119786 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 7009908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% trimetaphan infused at 100 drops per minute for three minutes, then 20 drops until the end of operation (Group I)
Number of subjects: 30
Study 7009908 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetaphan infused at 100 drops for six minutes, then 40 drops thereafter (Group II)
Number of subjects: 30
Study 7009908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trimetaphan)
Number of subjects: 30
Study 31011766 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS over the left PFC
Number of subjects: 36
Study 31011766 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 36
Study 28317673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrepid balanced tip
Number of subjects: 2
Study 28317673 — intervention group
Group type: COMPARATOR
Intervention: Kelman conventional tip
Number of subjects: 2
Study 26777884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 0
Study 26777884 — intervention group
Group type: COMPARATOR
Intervention: Different psychological intervention (active control)
Number of subjects: 0
Study 26777884 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (HC)
Number of subjects: 0
Study 25055847 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based stress management training (SMT) program
Number of subjects: 263
Study 25055847 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 263
Study 22560885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail invitation strategy (iFOBT)
Number of subjects: 19542
Study 22560885 — intervention group
Group type: COMPARATOR
Intervention: GP invitation strategy (iFOBT)
Number of subjects: 19542
Study 22560885 — intervention group
Group type: COMPARATOR
Intervention: Overall participation before reminder letter
Number of subjects: 19542
Study 22560885 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participation
Number of subjects: 19542
Study 22560885 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential and rural areas
Number of subjects: 19542
Study 22560885 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive iFOBT results
Number of subjects: 19542
Study 22560885 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy compliance
Number of subjects: 19542
Study 19668021 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P) 250 mg weekly injections
Number of subjects: 30
Study 19668021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19668021 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P)
Number of subjects: 30
Study 17521302 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drug users
Number of subjects: 138
Study 17521302 — intervention group
Group type: COMPARATOR
Intervention: Non-users of antiplatelet drugs
Number of subjects: 138
Study 15241691 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 40
Study 15241691 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 40
Study 15241691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (SE)
Number of subjects: 40
Study 15241691 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40
Study 11410112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GIK
Number of subjects: 20
Study 11410112 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative care
Number of subjects: 20
Study 9429742 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg orally (p.o.)
Number of subjects: 12
Study 9429742 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg intravenously (i.v.)
Number of subjects: 12
Study 9429742 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg orally (p.o.) and intravenously (i.v.)
Number of subjects: 12
Study 8220938 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxepa (10 capsules per day for 12 months)
Number of subjects: 64
Study 8220938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air-filled capsules, 10 per day for 12 months)
Number of subjects: 64
Study 3629186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cholecystokinin (CCK)
Number of subjects: 12
Study 3629186 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal
Number of subjects: 12
Study 3629186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bile acid load of 500 mg chenodeoxycholic acid (CDA)
Number of subjects: 12
Study 29567027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine carotid artery (BCA) grafts
Number of subjects: 100
Study 29567027 — intervention group
Group type: COMPARATOR
Intervention: Expanded polytetrafluoroethylene (ePTFE) grafts
Number of subjects: 100
Study 29567027 — intervention group
Group type: EXPERIMENTAL
Intervention: BCA and ePTFE grafts
Number of subjects: 100
Study 26198758 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 63
Study 26198758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 24473926 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatments for PTSD
Number of subjects: 353
Study 23113786 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-lesson curriculum focusing on healthful eating and physical activity
Number of subjects: 1689
Study 23113786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1689